Sunday 11 October 2015

Evenamide

INN name:
Lab Code(s):
find at Drugspider
Chemical name:
2-{[2-(3-Butoxyphenyl)ethyl]amino}-N,N-dimethylacetamide
Chemical structure:
Molecular formula:
C16H26N2O2
CAS registry number:
1092977-61-1
Originator:
Newron Pharmaceuticals
Class:
Antidepressants
Antiepileptic drugs
Antimanics
Antipsychotics
Non-opioid analgesics
Mechanism of action:
Nav1.3 voltage-gated sodium channel inhibitors
Nav1.7-voltage-gated-sodium-channel-inhibitors
Nav1.8 voltage-gated sodium channel inhibitors
WHO ATC code(s):
N02 (Analgesics)
N03A (Antiepileptics)
N05A (Antipsychotics)
N05B (Anxiolytics)
N07X (Other Nervous System Drugs)
EPhMRA code(s):
N2 (Analgesics)
N3 (Anti-Epileptics)
N5A (Antipsychotics)
N5B (Hypnotics/Sedatives)
N6A (Anti-Depressants and Mood Stabilisers)
N7X (All other CNS drugs)
Clinical trial(s):
ConditionsPhasesInterventionsStatus
Safety and Tolerability in Healthy VolunteersPhase 1Drug: NW-3509aCompleted

Tuesday 22 September 2015

Etripamil


INN name:
Etripamil

Lab codes:
find at Durgspider

Chemical name:
methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-
5-methylhexyl](methyl)amino}ethyl)benzoate

Molecular formula:
C27H36N2O4

Chemical Structure:
CAS Registry Number:
1593673-23-4


Originator:
Milestone Pharmaceuticals

Class:
Antiarrhythmics

Mechanism of Action:
Calcium channel antagonists

WHO ATC code:
C01 (Cardiac Therapy)
C01B (Antiarrhythmics, Class I and III)

EPhMRA code:
C1 (Cardiac Therapy)
C1B (Anti-Arrhythmics)

Clinical Trials:

Conditions
Phases
Status
Paroxysmal Supraventricular Tachycardia (PSVT)
Phase 2
Recruiting

Recent activities on the drug:

Guadecitabine


INN name:
Guadecitabine

Lab codes:
Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110

Chemical name:
2'-deoxy-5-azacytidylyl-(3'→5')-2'-deoxyguanosine
Molecular formula:
C18H24N9O10P

Chemical Structure:

CAS Registry Number:
929901-49-5

Originator:
SuperGen

Developer:
Astex Pharmaceuticals; Groupe Francophone des Myelodysplasies

Class:
Antineoplastics

Mechanism of Action:
Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors

WHO ATC code:
L01B (Antimetabolites)

EPhMRA code:
L1B (Antimetabolites)

Clinical Trials:

Conditions
Phases
Status
Leukemia, Myeloid, Acute
Phase 3
Recruiting
Non-small Cell Lung Cancer
Phase 2
Completed
MDS
Phase 2
Recruiting
Hepatocellular Carcinoma
Phase 2
Active, not recruiting
Previously Treated Metastatic Colorectal Cancer
Phase 1 / Phase 2
Recruiting
MDS;   CMML;   AML
Phase 1 / Phase 2
Active, not recruiting
Ovarian Cancer
Phase 1 / Phase 2
Active, not recruiting
Germ Cell Tumor
Phase 1
Recruiting
Metastatic Colorectal Cancer
Phase 1
Recruiting
Acute Myeloid Leukemia
Phase 1
Recruiting

Recent activities on the drug:

Monday 21 September 2015

Motolimod

INN name:

Motolimod
Lab codes:

VTX-2337

Chemical name:

2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide

Molecular formula:

C28H34N4O2
Chemical Structure:


CAS Registry Number:

926927-61-9
Originator:

Array BioPharma
Developer:

VentiRx Pharmaceuticals
Class:

Antineoplastics, immunomodulator
Mechanism of Action:

Toll-like receptor 8 (TLR8) agonist
WHO ATC code:

L03A-X
EPhMRA code:

L3A9

Clinical Trials:

Conditions
Phases
Interventions
Recruitment
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
Phase 2
Combination
Active, not recruiting
Carcinoma, Squamous Cell of Head and Neck
Phase 2
Combination
Active, not recruiting
Ovarian Cancer
Phase 1|Phase 2
Combination
Not yet recruiting
Low Grade B Cell Lymphoma
Phase 1|Phase 2
Combination
Terminated
 Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
Phase 1
Combination
Completed
Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Phase 1
Combination
Completed
Squamous Cell Carcinoma of the Head and Neck
Phase 1
Combination
Recruiting
Advanced Solid Tumors|Lymphoma
Phase 1
Alone
Completed

Friday 18 September 2015

Erdafitinib


INN name:
Erdafitinib

Lab codes:
JNJ-42756493

Chemical name:
N1-(3,5-dimethoxyphenyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N2-(propan-2-yl)ethane-1,2-diamine

Molecular formula:
C25H30N6O2

Chemical Structure:
CAS Registry Number:
1346242-81-6

Originator:
Astex Therapeutics

Developer:
Janssen Research & Development

Class:
Antineoplastics

Mechanism of Action:
Fibroblast growth factor receptor antagonists

WHO ATC code:
L01 (Antineoplastic Agents)

EPhMRA code:
L1 (Antineoplastics)

Clinical Trials:

Conditions
Phases
Status
Urothelial Cancer
Phase 2
Recruiting
Tumor or Lymphoma
Phase 1
Recruiting
Neoplasms;   Lymphoma;   Adenocarcinoma;   Esophagogastric Junction
Phase 1
Recruiting
Carcinoma, Hepatocellular
Phase 1
Recruiting

Recent activities on the drug: